|

Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia

RECRUITINGSponsored by Ruijin Hospital
Actively Recruiting
SponsorRuijin Hospital
Started2020-07-30
Est. completion2029-07-30
Eligibility
Age50 Years – 85 Years

Summary

This project is a multicenter observational study that establishes a longitudinal cohort of patients with Alzheimer's disease and other dementias based on neuroimaging, molecular imaging, biological and digital markers to explore new solutions such as dementia disease mechanism, diagnosis, condition evaluation, and prognosis assessment.

Eligibility

Age: 50 Years – 85 Years
Inclusion Criteria:

* Patients aged ≥50 and ≤85 years old, male or female;
* Meet the diagnostic criteria for dementia or MCI;
* Neuropsychological score: MMSE 15-28 points, CDR ≤ 1 point; ④ Patients and their families are informed and sign the informed consent form

Exclusion Criteria:

* The presence of other neurological diseases that may cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.);
* The presence of other systemic diseases that may cause cognitive impairment (such as liver dysfunction, renal dysfunction, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);
* Suffering from a disease that makes it impossible to cooperate with cognitive examinations;
* The presence of contraindications to MRI;
* The presence of mental and neurological retardation;
* Refusing to draw blood;
* Refusing to sign the informed consent form.

Conditions3

Alzheimer DiseaseAlzheimer's DiseaseImage

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.